P-1268. Evaluation of Mpox Coinfections with Hepatitis B, Hepatitis C, HIV, and Sexually Transmitted Infections During the Outbreak Peak In New York City

Abstract Background New York City (NYC) was an epicenter of the 2022 global mpox outbreak. Mpox is spread through skin-to-skin contact, including sexual contact, and there is a high prevalence of coinfections with HIV and other sexually transmitted infections (STI). The frequency of mpox and Hepatitis B/C virus (HBV/HCV) coinfections is unknown, though HBV/HCV can be sexually transmitted, and HBV/HCV prevention and treatment are part of syndemic approaches with HIV/STI. We evaluated mpox coinfections in NYC, focusing on HBV/HCV. Demographic characteristics of people with mpox-only and people with mpox and coinfection, New York City, May 18–August 19, 2022 Methods We performed descriptive analyses and assessed coinfections using matched NYC Health Department surveillance registries for HBV/HCV, HIV, STI (chlamydia, gonorrhea, early syphilis), and mpox during the outbreak peak (May 18–August 19, 2022). Registries included all patient laboratory reports for each infection and demographics: age at mpox diagnosis, sex at birth, gender identity, race/ethnicity, NYC borough of residence, and area-based poverty level. People with resolved HCV were excluded. Results During the analytic period, 2925 people were diagnosed with mpox; 1299 (44.4%) were living with diagnosed HIV, 32 (1.1%) with HBV, and 30 (1.0%) with HCV, with half (1541; 52.7%) diagnosed with STI in the prior 12 months (Table 1). Coinfections of mpox and HBV/HCV were more common for people living in very high poverty areas (HBV-mpox: 37.5%, HCV-mpox: 40%). For non-Hispanic Black and Latino/Hispanic people, mpox coinfections with HIV (40.3% and 44.2%, respectively); HBV (37.5%; 43.8%); HCV (36.7%; 53.3%); and recent STI (30.1%, 37.1%) were more frequent than mpox monoinfection (17.9%; 31.2%). For non-Hispanic white people, coinfections with HIV (12.6%); HBV (12.5%); HCV (10%); and recent STI (22.3%) were less frequent than mpox monoinfection (32.9%). Conclusion Among people diagnosed with mpox, coinfection rates with HBV/HCV were low compared with HIV/STI. This might reflect sexual transmission as a less common driver of HBV/HCV infection in communities affected by mpox. There were more coinfections in Black and Latino/Hispanic people and more HBV/HCV coinfections in people living in very high poverty areas. Place-based HBV/HCV screening could be beneficial in future mpox outbreaks, and universal HIV/STI screening at mpox diagnosis should continue. Disclosures All Authors: No reported disclosures